PriceTargets.com logo

OptimizeRx - OPRX Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $14.50
  • Forecasted Upside: 141.26%
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$6.01 As of 10/22/2024 01:00 AM ET
▼ -0.06 (-0.99%)

This chart shows the closing price for OPRX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New OptimizeRx Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OPRX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OPRX

Analyst Price Target is $14.50
▲ +141.26% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for OptimizeRx in the last 3 months. The average price target is $14.50, with a high forecast of $18.50 and a low forecast of $11.00. The average price target represents a 141.26% upside from the last price of $6.01.

This chart shows the closing price for OPRX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 5 contributing investment analysts is to moderate buy stock in OptimizeRx. This rating has held steady since December 2023, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/1/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/30/2023
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/28/2023
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/26/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/24/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/22/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/22/2024

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
8/16/2024Royal Bank of CanadaLower TargetOutperform ➝ Outperform$17.00 ➝ $14.00
8/12/2024BarclaysLower TargetEqual Weight ➝ Equal Weight$15.00 ➝ $11.00
7/25/2024B. RileyInitiated CoverageBuy$18.50
6/21/2024JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$16.00 ➝ $16.00
5/15/2024JMP SecuritiesBoost TargetMarket Outperform ➝ Market Outperform$15.00 ➝ $16.00
5/15/2024Stifel NicolausReiterated RatingBuy ➝ Buy$13.00 ➝ $13.00
4/16/2024JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$15.00
4/4/2024JMP SecuritiesInitiated CoverageMkt Outperform$15.00
4/1/2024Stifel NicolausReiterated RatingBuy ➝ Buy$13.00
4/1/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$17.00
1/10/2024Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$14.00 ➝ $17.00
1/3/2024BarclaysInitiated CoverageEqual Weight$15.00
8/15/2023Roth MkmLower TargetBuy ➝ Buy$31.00 ➝ $20.00
8/15/2023Lake Street CapitalLower TargetBuy ➝ Buy$18.00 ➝ $13.00
8/15/2023Royal Bank of CanadaLower TargetOutperform ➝ Outperform$18.00 ➝ $14.00
8/15/2023B. RileyLower TargetBuy ➝ Buy$28.00 ➝ $18.00
8/15/2023Stifel NicolausLower TargetBuy ➝ Buy$16.00 ➝ $13.00
3/21/2023William BlairReiterated RatingOutperform
3/9/2023Roth CapitalReiterated RatingBuy
3/9/2023Lake Street CapitalLower Target$25.00 ➝ $18.00
3/9/2023B. RileyLower Target$30.00 ➝ $28.00
3/9/2023Stifel NicolausLower Target$19.00 ➝ $16.00
3/9/2023Royal Bank of CanadaLower TargetOutperform$22.00 ➝ $18.00
2/2/2023B. RileyReiterated RatingBuy$30.00
1/27/2023Leerink PartnersReiterated RatingOutperform
10/31/2022Stifel NicolausInitiated CoverageBuy$19.00
8/10/2022Leerink PartnersLower TargetOutperform$38.00 ➝ $30.00
8/10/2022Piper SandlerLower TargetNeutral$29.00 ➝ $16.00
7/20/2022B. RileyLower TargetBuy$71.00 ➝ $56.00
7/15/2022Leerink PartnersInitiated CoverageOutperform$38.00
7/1/2022Piper SandlerInitiated CoverageNeutral$29.00
5/5/2022Royal Bank of CanadaLower Target$100.00 ➝ $50.00
5/5/2022Roth CapitalLower Target$112.00 ➝ $66.00
2/16/2022Lake Street CapitalLower TargetBuy$98.00 ➝ $76.00
11/10/2021Roth CapitalBoost TargetBuy$85.00 ➝ $112.00
11/10/2021Royal Bank of CanadaBoost TargetOutperform$67.00 ➝ $100.00
11/9/2021William BlairReiterated RatingOutperform
10/18/2021B. RileyReiterated RatingBuy$102.00
8/5/2021B. RileyBoost TargetBuy$80.00 ➝ $95.00
5/7/2021B. RileyBoost TargetBuy$75.00 ➝ $80.00
4/12/2021Royal Bank of CanadaInitiated CoverageOutperform$65.00
2/25/2021B. RileyBoost TargetBuy$60.00 ➝ $75.00
2/25/2021Roth CapitalBoost TargetTop Pick ➝ Buy$70.00 ➝ $85.00
1/26/2021Lake Street CapitalBoost TargetBuy$40.00 ➝ $54.00
1/7/2021Lake Street CapitalBoost Target$26.00 ➝ $40.00
1/7/2021Roth CapitalBoost TargetTop Pick ➝ Buy$40.00 ➝ $70.00
1/4/2021B. RileyBoost TargetOutperform ➝ Buy$34.00 ➝ $50.00
11/10/2020Lake Street CapitalBoost TargetBuy$21.00 ➝ $26.00
11/10/2020B. RileyBoost TargetBuy$30.00 ➝ $34.00
9/14/2020Roth CapitalBoost TargetBuy$30.00 ➝ $40.00
8/6/2020B. RileyBoost Target$22.00 ➝ $28.00
8/6/2020Lake Street CapitalBoost TargetBuy$17.00 ➝ $20.00
6/8/2020Lake Street CapitalBoost TargetReduce ➝ Buy$14.00 ➝ $17.00
5/5/2020B. RileyBoost TargetBuy$18.00 ➝ $22.00
4/7/2020B. RileyLower TargetBuy$20.00 ➝ $18.00
1/3/2020William BlairInitiated CoverageOutperform
12/30/2019B. RileyLower TargetBuy$21.00 ➝ $20.00
(Data available from 10/23/2019 forward)

News Sentiment Rating

1.82 (Strong Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/27/2024
  • 6 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
4/26/2024
  • 3 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
5/26/2024
  • 6 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/25/2024
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/25/2024
  • 3 very positive mentions
  • 10 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
8/24/2024
  • 4 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/23/2024
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/23/2024

Current Sentiment

  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

OptimizeRx logo
OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events. The company was founded in 2006 and is based in Waltham, Massachusetts.
Read More

Today's Range

Now: $6.01
Low: $5.84
High: $6.10

50 Day Range

MA: $7.58
Low: $6.01
High: $8.60

52 Week Range

Now: $6.01
Low: $5.84
High: $16.65

Volume

175,502 shs

Average Volume

142,114 shs

Market Capitalization

$110.10 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.27

Frequently Asked Questions

What sell-side analysts currently cover shares of OptimizeRx?

The following sell-side analysts have issued research reports on OptimizeRx in the last twelve months: B. Riley, Barclays PLC, JMP Securities, Royal Bank of Canada, and Stifel Nicolaus.
View the latest analyst ratings for OPRX.

What is the current price target for OptimizeRx?

5 Wall Street analysts have set twelve-month price targets for OptimizeRx in the last year. Their average twelve-month price target is $14.50, suggesting a possible upside of 141.3%. B. Riley has the highest price target set, predicting OPRX will reach $18.50 in the next twelve months. Barclays PLC has the lowest price target set, forecasting a price of $11.00 for OptimizeRx in the next year.
View the latest price targets for OPRX.

What is the current consensus analyst rating for OptimizeRx?

OptimizeRx currently has 1 hold rating and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for OPRX.

What other companies compete with OptimizeRx?

Other companies that are similar to OptimizeRx include Limelight Networks, ASAP, Sohu.com, OmniAb and Absci. Learn More about companies similar to OptimizeRx.

How do I contact OptimizeRx's investor relations team?

OptimizeRx's physical mailing address is 400 WATER STREET SUITE 200, ROCHESTER MI, 48307. The company's listed phone number is (248) 651-6568 and its investor relations email address is [email protected]. The official website for OptimizeRx is www.optimizerx.com. Learn More about contacing OptimizeRx investor relations.